What's in Sumitomo Pharma Co., Ltd.'s pipeline?

Sumitomo Pharma Co., Ltd. has 11 drugs in our index: 0 marketed, 0 filed, 6 in Phase 3, 2 in Phase 2, 3 in Phase 1.

Which companies overlap with Sumitomo Pharma Co., Ltd.'s portfolio?

Top competitors by shared drug class: Qilu Pharmaceutical Co., Ltd., AstraZeneca, Eli Lilly and Company, Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sumitomo-pharma-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Sumitomo Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Sumitomo Pharma Co., Ltd. pipeline: 0 marketed, 0 filed, 6 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 6 Phase 3 2 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Amrubicin hydrocloride	Amrubicin hydrocloride	phase 3	Topoisomerase II inhibitor; anthracycline	Topoisomerase II	Oncology
DSP-5423P Active-to-Flex	DSP-5423P Active-to-Flex	phase 3	Dopamine D1 receptor partial agonist	Dopamine D1 receptor (DRD1)	Neurology/Psychiatry
SM-13496	SM-13496	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
DSP-5423P Placebo-to-Flex	DSP-5423P Placebo-to-Flex	phase 3
SM-13496 (lurasidone HCl)	SM-13496 (lurasidone HCl)	phase 3	atypical antipsychotic	serotonin 2A receptor, dopamine D2 receptor	Psychiatry
ranirestat, (AS-3201)	ranirestat, (AS-3201)	phase 3	Aldose reductase inhibitor	Aldose reductase	Endocrinology / Diabetes

Therapeutic area mix

Diabetes · 1
Endocrinology / Diabetes · 1
Neurology/Psychiatry · 1
Oncology · 1
Psychiatry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Qilu Pharmaceutical Co., Ltd. · 2 shared drug classes
AstraZeneca · 2 shared drug classes
Eli Lilly and Company · 2 shared drug classes
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 2 shared drug classes
Takeda · 2 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class
AJU Pharm Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sumitomo Pharma Co., Ltd.:

Cite this brief

Drug Landscape (2026). Sumitomo Pharma Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sumitomo-pharma-co-ltd. Accessed 2026-06-10.